These products are not intended to diagnose, treat, cure, or prevent any disease. When using this product, do not drive or operate machinery. To report a problem or complaint with this product click here.
Aceclofenac 100mg + Paracetamol 325mg + Serratiopeptidase 15mg Tablets Note: This page is only for the general information purpose and not for self-use.
This should not be used as a substitute for the actual medical guidance and treatment of the healthcare professional.
Aceclofenac 100mg + Paracetamol 325mg + Serratiopeptidase 15mg Tablets is the pharmaceutical combination formulation consisting of three active pharmaceutical ingredients (apis) in one solid dosage form (tablets). The Aceclofenac 100mg + Paracetamol 325mg + Serratiopeptidase 15mg Tablets is dispensed as a solid preparation (tablets) comprising of Aceclofenac 100mg, Paracetamol 325mg, and Serratiopeptidase 15mg prepared in a formulation process.
Each of the three active pharmaceutical ingredients must be individually characterized to develop a three-ingredient tablet. The unique particle size, flow properties, stability, compatibility and processing behavior of each active pharmaceutical ingredient must be taken into account.
Formulation development strategy assisting the manufacturer to identify the relevant processing conditions and the selection of pharmaceutical excipients. The manufacturing process, as a general rule, will include raw-material testing, dispensation, mixing, granulation, compression, inspection, quality control, and finally packaging.
Consistency throughout each step of production is required to have a finished piece that is consistent and professionally crafted.
Active Ingredients & Composition: This formulation contains Aceclofenac 100mg, Paracetamol 325mg and Serratiopeptidase 15mg. These Active ingredients are listed in the formulation in a single tablet in the strength as specified in the formulation.
Prior to choosing excipients and manufacturing technology, the formulation scientist will assess the physical and chemical properties of the three ingredients. During product development the following parameters may be assessed particle shape, size and surface, flowability, water content, solubility, compatibility and stability.
Serratiopeptidase is an enzyme-based pharmaceutical ingredient and formulation and manufacturing conditions are important considerations. The appropriate formulation processing conditions are chosen to preserve the features of the formulation.
Optional excipients can be added to help blending, granulation, powder flow, compression, tablet integrity, and other physical characteristics. The formula is balanced to provide adequate uniformity of the three actives.
Aceclofenac 100mg + Paracetamol 325mg + Serratiopeptidase 15mg Tablets are formulated and developed after consideration of the compatibility of active pharmaceutical ingredients and excipients chosen.
Each various ingedients may react differently to moisture, temperature, compressing force and other manufacturing conditions which would be considered in the formulation development for the minimum manufacturing requirements.
The formulation development process involves laboratory studies, compatibility studies, testing for maximum possible quantities of Excipients as well as evaluation of tablets. The aim is to develop a reproducible formulation suitable for large-scale manufacture.
Specialized focus could be put to the handling and processing properties of the Serratiopeptidase ingredient as it's an enzyme based ingredient. For the manufacturing and storage of the ingredient the conditions are taken into consideration to ensure the obligatory quality of the product.
3. All three active ingredients should be evenly distributed This is another reason why it is so important to achieve good mixing and a tightly controlled manufacturing process.
Pharmaceutical Grade Raw Materials are procured, tested and released for manufacturing of Aceclofenac 100mg Paracetamol 325mg Serratiopeptidase 15mg Tablets. Testing of Pharmaceutical raw materials The raw materials are tested as per the requirements and specifications.
Process options for production can include dispensing, sifting, blending, granulation, drying, lubrication, compression, dedusting, inspection and packaging, all depending on the process you choose.
Various in-process control can be made during manufacture like blend uniformity, moisture content, weight of individual tablet, tab thickness, hardness, appearance etc. These controls are carried out to monitor the quality of the product.
Testing of finished product may be done for appearance, weight variation, hardness, friability, disintegration, assay, content uniformity, and other relevant quality tests.
In a three component formulation, assays, there should be other analytical methods which are there for the individual active ingredients. Quality testing will assist in confirming the Quality of the finished product is according to specification of Aceclofenac, Paracetamol and Serratiopeptidase.
Accurate batch documentation and traceability reinforce the controlled system of pharmaceutical manufacturing.
Stability is a key factor in pharmaceutical combination tablets development. Aceclofenac 100mg + Paracetamol 325mg + Serratiopeptidase 15mg Tablets may be stability tested under a specified environment to observe physical and chemical parameters over a period of time.
Stability studies assist manufacturers in determining package requirements and product specifications. This is especially true for formulations which include enzyme-based ingredients, where environmental control may be a significant factor.
The primary or secondary packaging is chosen to offer adequate protection during storage, transportation and distribution. Suitable primary and secondary packaging systems can help sustain the integrity of the product.
Typically, the packaging label contains product name, composition, strengths, batch number, manufacturing details, expiry details, manufacturer details and other relevant regulatory details.
The benefits of packaging for the pharmaceutical industry also include brand development and uniform branding.
Aceclofenac 100mg + Paracetamol 325mg + Serratiopeptidase 15mg Tablets can be a part of a varied pharma product offerings. Solid combination products with two or more active ingredients can contribute to a range of multi-product offerings.
Companies like makers, distributors, franchising firms and marketers determining to incorporate items to their portfolio consider what is the formulation quality, production potential, raw-material requirements, packaging, documentation as well as source security.
A well balanced pharmaceutical portfolio may contain various other forms of pharmaceutical preparations such as tablets, combination medicines, capsules, topical items and much more. The regular production of all these various forms of drug remains a component of an expert company profile.
Ensuring a constant flow of the product manufacturing and supply chain management is another factor in making sure it is always accessible. Proper production scheduling, quality control procedures, inventory management and correct packaging all play a part in an effective distribution.
Factors affecting the quality of Aceclofenac 100mg + Paracetamol 325mg + Serratiopeptidase 15mg Tablets There are many factors which determine the overall quality of Aceclofenac 100mg + Paracetamol 325mg + Serratiopeptidase 15mg Tablets which start from raw material sourcing, formulation, and design to manufacturing, testing, packaging, and distribution.
Quality-oriented manufacturing process involves controlled manufacturing environment, use of pharmaceutical quality ingredients and raw materials, batch-by-batch testing and documentation, equipment and processes on scheduled maintenance, and batch traceability.
Special focus could be given to the assay, uniformity of active-ingredient content, tablet hardness, friability, disintegration, stability, enzyme-specific issues of formulation, packaging integrity and variations between different batches.
Pharmaceutical manufacturers can focus on assuring safe production of medications and a more robust overall product portfolio by ensuring these standards are up to date. When quality-control processes are implemented, pharmaceutical developers can successfully distinguish between product and process variations.
We combine quality, innovation, and strong distribution to help our partners grow successfully in the pharma market.
The company is offering business opportunity for scalable and sustainable returns to its associates. We are engaged in discovery, development and commercialization of pharmaceutical medicine keeping in mind its quality and affordability.
© Novolilly 2025. All Rights Reserved – Developed & Managed By Kavir Infotech